Clinical Trials for Other Solid Tumor

Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adults with advanced non-small cell lung cancer (NSCLC), who have progressed after standard therapy and meet specific criteria including a PD-L1 score of at least 1%, receiving pembrolizumab, a PD-1 inhibitor that enhances immune response, combined with inhaled antibiotics aztreonam and vancomycin to address lung microbiome dysbiosis.

ClinicalTrials.gov ID: NCT05777603

A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial is enrolling patients with advanced solid tumors who have exhausted standard treatments, evaluating the safety and efficacy of ACTM-838, a novel investigational monotherapy that targets resistant tumors by potentially novel mechanisms to inhibit tumor growth.

ClinicalTrials.gov ID: NCT06336148

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates BBT-207, which targets EGFR mutations resistant to current therapies, in patients with advanced NSCLC who have progressed after treatment with third-generation EGFR TKIs such as osimertinib or lazertinib and have specific EGFR mutations. The open-label study aims to evaluate safety, pharmacokinetics, and preliminary efficacy across dose escalation and expansion phases.

ClinicalTrials.gov ID: NCT05920135

QUILT-3.055: a Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with PD-1/PD-L1 Immune Checkpoint Inhibitors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the efficacy and safety of combination immunotherapies in patients with advanced solid tumors progressing after PD-1/PD-L1 inhibitors, utilizing treatments such as the investigational IL-15 superagonist N-803 combined with nivolumab, pembrolizumab, or PD-L1 t-haNK, with an additional cohort receiving docetaxel.

ClinicalTrials.gov ID: NCT03228667

A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets participants with advanced solid tumors linked to MAPK pathway mutations (KRAS, HRAS, NRAS, BRAF, CRAF, NF1) who have exhausted standard treatments, using the investigational MAPK pathway inhibitor DCC-3084 as monotherapy or combined with other anti-cancer drugs. Candidates must have an ECOG status of 0-1 and a life expectancy of over six months.

ClinicalTrials.gov ID: NCT06287463

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial is for adult patients with advanced or metastatic solid tumors, including specific cohorts like SCLC, NSCLC, ESCC, CRPC, melanoma, HCC, and cervical cancer, unresponsive to standard treatments, and it investigates the safety and efficacy of DB-1311, an antibody-drug conjugate targeting B7-H3, to assess its antitumor activity and determine optimal dosing.

ClinicalTrials.gov ID: NCT05914116

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This clinical trial is evaluating adagrasib, an oral KRAS G12C inhibitor, as monotherapy and in combination with pembrolizumab, versus pembrolizumab alone, in treatment-naïve patients with unresectable, locally advanced, or metastatic non-small cell lung cancer harboring a KRAS G12C mutation, with varying PD-L1 expression levels.

ClinicalTrials.gov ID: NCT04613596

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients with metastatic EGFR-mutant non-small cell lung cancer who have detectable plasma EGFR mutations despite starting osimertinib and compares progression-free survival between treatment with osimertinib alone and in combination with chemotherapy (carboplatin and pemetrexed).

ClinicalTrials.gov ID: NCT04410796

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial examines the efficacy and safety of combining ADI-PEG 20, an investigational enzyme targeting arginine metabolism, with gemcitabine and docetaxel in adult patients with extensive-stage small cell lung cancer or metastatic non-small cell lung cancer who have progressed after frontline therapy. Participants must meet specific criteria, including having an ECOG performance status ≤ 1, and should not have previously received ADI-PEG 20 or gemcitabine.

ClinicalTrials.gov ID: NCT05616624

A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial enrolls adult patients with histologically or cytologically confirmed advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations, who have undergone at least one line of standard systemic treatment. Participants receive the investigational oral drug IMM-6-415, targeting these mutations, administered daily across 21-day cycles to evaluate safety, tolerability, and preliminary anti-tumor activity.

ClinicalTrials.gov ID: NCT06208124